Chantix (varenicline): Label Change – Risk of Certain Cardiovascular Adverse Events

Audience: Family Medicine, Cardiology [Posted 06/16/2011]

ISSUE: FDA notified healthcare professionals and patients that the Prescribing Information for this drug product will be strengthened to inform the public that use of varenicline may be…



Related posts:

  1. 5-alpha reductase inhibitors (5-ARIs): Label Change – Increased Risk of Prostate Cancer Audience: Urology, Family Medicine, Internal Medicine Drugs in the 5-ARI...
  2. Zocor (simvastatin): Label Change – New Restrictions, Contraindications, and Dose Limitations Audience: Family Practice, Cardiology, Pharmacy Simvastatin sold under the brand-name...
  3. Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events Audience: Endocrinology, Cardiology includes Avandia, Avandamet, and Avandaryl [UPDATED 05/18/2011]...
  4. Topamax (topiramate): Label Change – Risk For Development of Cleft Lip and/or Cleft Palate in Newborns Audience: Neurology, OB/GYN ISSUE: FDA notified healthcare professionals and patients...